FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine.
The company was founded in 2000 in the Netherlands, is operational in 40 countries with a network of 6,000 clinics worldwide. ESPERITE serves clients in its state-of-the-art lab facilities in Geneva coupled with ultra-modern processing and storage facilities in Belgium, Switzerland, Germany, Dubai, South Africa and Portugal. ESPRITE is organised in 3 main business units: CryoSave, Genoma and The Cell Factory.
Its family stem cell bank, CryoSave stores almost 275,000 samples from umbilical cord blood and cord tissue, and is the leading international stem cell processing and cryo-conservation company and the largest family stem cell bank in Europe. Genoma, active in proteomics and genomics predictive medicine is expanding its launch activities for Tranqullity, the most accurate non-invasive prenatal trisomy test (NIPT), Verity, the most advanced test for more than 110 Metabolic disorders, and REALITY, the First High-tech Genetic Test for Autism. The Cell Factory, Esperite Group's R&D Division, is focused clinical translation, commercialization of the advanced cell therapy medicinal products and development of new therapies in the field of regenerative medicine.
The Esperite website www.esperite.com provides detailed country websites in a rainbow of languages offering parents to express their interests in Esperite services. In all countries present Esperite relies upon trained and locally based staff available to parents and the medical community to explain the benefits of umbilical cord blood storage and the advantages of storing a child’s stem cells with Esperite.
The Cell Factory, pursues its strategy of building up the clinical grade development of advanced therapy products in its state-of-the-art laboratories in Belgium. The Cell Factory is implementing the technology for stem cell bioproduction under clinical quality (GMP) guidelines using synthetic (animal products free) culture media. This technology allows for efficient production of stem cells at large scale required for clinical translation in responsible regenerative medicine.
The Cell Factory is preparing a multicentre clinical trial following GCP-ICH standards, for investigation of new treatment of Cerebral Palsy using dual infusion of two types of stem cells derived from umbilical cord blood and cord tissue processed by CryoSave.
The clinical trial aims to demonstrate safety and preliminary efficacy of sequential intravenous infusion of the ex vivo expanded mesenchymal stem cells (MSC) derived from cord tissue and the cord blood stem cells. The study will use, for the first time in clinical research, autologous MSC derived from cryopreserved cord tissue.